Good regulatory progress but more needed, China says
This article was originally published in Scrip
China's State Council has published a white paper outlining the measures the country has taken over the past few years to improve the regulation of pharmaceuticals and other medical products, which concludes that while "remarkable progress" has been made the country "is still facing many difficulties and problems".
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.